La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

PYC Therapeutics Gestione

Gestione criteri di controllo 4/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Rohan Hockings

Amministratore delegato

AU$433.2k

Compenso totale

Percentuale dello stipendio del CEO	91.2%
Mandato del CEO	4.2yrs
Proprietà del CEO	n/a
Durata media del management	4.2yrs
Durata media del Consiglio di amministrazione	3.6yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Rohan Hockings rispetto agli utili di PYC Therapeutics?
Data	Compenso totale	Stipendio	Guadagni aziendali
Jun 30 2024	AU$433k	AU$395k	-AU$38m
Mar 31 2024	n/a	n/a	-AU$30m
Dec 31 2023	n/a	n/a	-AU$22m
Sep 30 2023	n/a	n/a	-AU$22m
Jun 30 2023	AU$438k	AU$395k	-AU$23m
Mar 31 2023	n/a	n/a	-AU$23m
Dec 31 2022	n/a	n/a	-AU$24m
Sep 30 2022	n/a	n/a	-AU$19m
Jun 30 2022	AU$418k	AU$395k	-AU$14m
Mar 31 2022	n/a	n/a	-AU$15m
Dec 31 2021	n/a	n/a	-AU$17m
Sep 30 2021	n/a	n/a	-AU$17m
Jun 30 2021	n/a	n/a	-AU$18m
Mar 31 2021	n/a	n/a	-AU$15m
Dec 31 2020	n/a	n/a	-AU$12m
Sep 30 2020	n/a	n/a	-AU$9m
Jun 30 2020	AU$471k	AU$395k	-AU$7m
Mar 31 2020	n/a	n/a	-AU$6m
Dec 31 2019	n/a	n/a	-AU$5m
Sep 30 2019	n/a	n/a	-AU$5m
Jun 30 2019	AU$482k	AU$395k	-AU$4m
Mar 31 2019	n/a	n/a	-AU$4m
Dec 31 2018	n/a	n/a	-AU$5m
Sep 30 2018	n/a	n/a	-AU$6m
Jun 30 2018	AU$377k	AU$84k	-AU$7m

Compensazione vs Mercato: La retribuzione totale di Rohan ($USD 293.90K ) è inferiore alla media delle aziende di dimensioni simili nel mercato Australian ($USD 838.87K ).

Compensazione vs guadagni: La retribuzione di Rohan è stata coerente con le performance aziendali dell'ultimo anno.

AMMINISTRATORE DELEGATO

Rohan Hockings (41 yo)

4.2yrs

Mandato

AU$433,210

Compensazione

Dr. Rohan Hockings, MBBS (Hons.), J.D., G.D.L.P, has been Chief Executive Officer at PYC Therapeutics Limited since August 2020. He served as Chief Strategy Officer at PYC Therapeutics Limited until August...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Rohan Hockings	CEO & Executive Director	4.2yrs	AU$433.21k	Nessun dato
Andrew Taylor	CFO & Company Secretary	2.5yrs	Nessun dato	Nessun dato
Kevin Hart	Company Secretary	7.3yrs	AU$165.90k	Nessun dato

4.2yrs

Durata media

Gestione esperta: Il team dirigenziale di PYC è considerato esperto (durata media dell'incarico 4 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Rohan Hockings	CEO & Executive Director	5.9yrs	AU$433.21k	Nessun dato
Michael Rosenblatt	Independent Non-Executive Director	3.6yrs	AU$86.67k	Nessun dato
David Birch	Member of Ophthalmology Clinical Advisory Board	3.2yrs	Nessun dato	Nessun dato
Jason Haddock	Independent Director	3.6yrs	AU$86.67k	Nessun dato
Alan Tribe	Non-Executive Chair of the Board	6.5yrs	AU$70.00k	34.02% A$ 317.5m
Fred Chen	Member of Scientific Advisory Board & Member of Ophthalmology Clinical Advisory Board	5.1yrs	Nessun dato	Nessun dato
Mark Pennesi	Member of Ophthalmology Clinical Advisory Board	3.2yrs	Nessun dato	Nessun dato
Jacque Duncan	Member of Ophthalmology Clinical Advisory Board	3.2yrs	Nessun dato	Nessun dato

3.6yrs

Durata media

65yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di PYC sono considerati esperti (durata media dell'incarico 5.2 anni).

PYC Therapeutics Gestione

Gestione criteri di controllo 4/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

PYC Therapeutics Limited, Annual General Meeting, Nov 13, 2024

Insufficient new directors

PYC Therapeutics Limited, Annual General Meeting, Nov 24, 2023

Non-Executive Chair of the Board recently bought AU$85k worth of stock

PYC Therapeutics Limited, Annual General Meeting, Jul 05, 2023

Pyc Appoints Andrew Taylor as Joint Company Secretary

Recent updates

PYC Therapeutics Limited, Annual General Meeting, Nov 13, 2024

Insufficient new directors

PYC Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 74.657302 million.

Forecast to breakeven in 2026

PYC Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 74.657343 million.

New major risk - Financial position

Pyc Therapeutics Announces the Results of A Study Conducted in Human 3-Dimensional Models Derived from Patients with End-Stage Renal Failure Due to Autosomal Dominant Polycystic Kidney Disease

PYC Therapeutics Limited, Annual General Meeting, Nov 24, 2023

New minor risk - Financial data availability

PYC Therapeutics Limited Announces US FDA Designates PYC's Lead as a Fast Track Development Program

Non-Executive Chair of the Board recently bought AU$85k worth of stock

PYC Therapeutics Limited, Annual General Meeting, Jul 05, 2023

Pyc Appoints Andrew Taylor as Joint Company Secretary

PYC Therapeutics Limited Announces the Submission of Investigational New Drug Application with the US Food and Drug Administration

High number of new and inexperienced directors

PYC Therapeutics Limited Announces Successful Toxicology Studies Pave Way for Human Trials

PYC Therapeutics Limited, Annual General Meeting, Nov 23, 2022

PYC Therapeutics Limited Announces Central Nervous System Drug Program Added to PYC Pipeline

Non-Executive Chair of the Board recently bought AU$103k worth of stock

PYC Therapeutics Limited Announces Exemplary PK Study Results Move RP11 Program Closer to First in Human Trials

High number of new and inexperienced directors

PYC Therapeutics Limited Enters into the Next Phase of Preclinical Development for VP-001

PYC Therapeutics Announces Comprehensive Preclinical Results Demonstrating VP-002 Program's Potential as the First Disease Modifying Therapy for Autosomal Dominant Optic Atrophy

PYC Therapeutics to Develop A New Generation of RNA Therapeutics

PYC Therapeutics Limited Announces Second Investigational Drug Candidate Restores the Levels of the Target Protein Towards Normal in Models Derived from Patients with the Indicated Disease ­ Autosomal Dominant Optic Atrophy

PYC Therapeutics Limited Appoints Michael Rosenblatt, MD, to Its Board of Directors

PYC's Lead Investigational Drug, VP-001, Demonstrates Another Key Functional Improvement in Patient-Derived Models - a First for Any Rp11 Treatment to-Date

PYC Therapeutics Names Glenn Noronha as Chief Development Officer

Non-Executive Chair of the Board recently bought AU$81k worth of stock

PYC Therapeutics Limited Announces Visual Evidence of Lead Drugs Efficacy

PYC Therapeutics Limited Appoints Sahm Nasseri as CEO of Us Operations and as Director of the Board

PYC Therapeutics Announces to Developing New Treatments for Severe Unmet Patient Needs

Doug Huey Not to Seek Re Election At PYC Therapeutics Limited

PYC Therapeutics Limited Develops New Treatments for Severe Unmet Patient Needs

PYC Therapeutics Limited Files for Intellectual Property Protection for the New Drug Candidate

PYC Therapeutics Limited Announces CEO Changes

Analisi delle retribuzioni degli amministratori delegati

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Gruppo dirigente

Durata media

Membri del Consiglio di amministrazione

Durata media

Età media

PYC Therapeutics Limited Announces Second Investigational Drug Candidate Restores the Levels of the Target Protein Towards Normal in Models Derived from Patients with the Indicated Disease Autosomal Dominant Optic Atrophy